https://www.selleckchem.com/products/smip34.html 9±0.5%) and control (93.8±0.6%). The early postoperative satisfaction in control group was much lower than HBOT group (52.9% vs 88.2%), whereas all patients showed satisfaction with the final result. Hyperbaric oxygen therapy is able to minimize the postsurgical follicle shedding and lead to less folliculitis and itching, which provides evidence for HBOT to act as an adjuvant therapy for hair transplantation surgery. Hyperbaric oxygen therapy is able to minimize the postsurgical follicle shedding and lead to less folliculitis and itching, which provides evidence for HBOT to act as an adjuvant therapy for hair transplantation surgery. To estimate the cost-effectiveness of tranexamic acid (TXA) use to prevent postpartum haemorrhage. A trial-based economic evaluation. Fifteen French university maternity hospitals. Women enrolled in the TRAAP randomised controlled trial comparing TXA versus placebo in women with vaginal delivery. TRAAP failed to show a reduction in postpartum haemorrhage of at least 500ml in the intervention arm but evidenced significant lower rates of secondary outcomes related to blood loss. We estimated direct medical costs from within-trial hospital resources collected prospectively from the study report form. All resources were costed at their value to the hospital. We estimated incremental cost per incremental haemorrhage averted. Among the 4079 women in the TRAAP trial, data necessary to calculate costs were available for 3836 (94.0%). The average total costs in the TXA and control groups were €2278±388 and €2288±409 per woman, respectively (P=0.79). In women with postpartum haemorrhage of at least 500ml (trial primary endpoint), costs were €2359±354 and €2409±525 (P=0.14); for provider-assessed clinically significant postpartum haemorrhage and postpartum haemorrhage of at least 1000ml, costs were respectively €2316±347 versus €2381±521 (P=0.22) and €2321±318 versus €2411±590 (P=0.35) in the tranex